

DAFTAR PUSTAKA

1. Kemenkes RI. Profil Kesehatan Indonesia 2018 [online]. 2019. p.1-12. <http://www.depkes.go.id/resources/download/pusdatin/profil-kesehatan-indonesia/>. [Accessed 2020 October 16]
2. Paula AA, Falcao MCN, dan Pacheco AG. Metabolic syndrome in HIV-infected individuals : underlying mechanisms and epidemiological aspects. *AIDS Res Ther.* 2013;10:32
3. Ceccato MGB, Bonolo PF, Neto AIS, Araujo FS, Freitas MI. Antiretroviral therapy – associated dyslipidemia in patients from a reference center in Brazil. *Braz J Med and Biol Res.* 2011;44:1177-79
4. Nery WM, Turchi CM, Martelli, Turchi MD. Dyslipidemia in AIDS patients on highly active antiretroviral therapy. *Braz J Infect Dis.* 2011; 15(2):151-3
5. Ji S, Xu Y, Han D, Peng X, Lu X, Brockmeyer NH, Wu N. Changes in lipid Indices in HIV+ Cases on HAART. *BioMed Res Int.* 2019;1:1-2
6. Pau AK, George JM. Antiretroviral Therapy : Current Drugs. *Infect Dis Clin North Am.* 2014;28(3):371-402
7. Yeni P. Update on HAART in HIV. *J Hepatol.* 2006;44(1 suppl):S100-3
8. Arts EJ, Hazuda DJ. HIV-1 Antiretroviral Drug Therapy. *Cold Spring Harb Perspect Med.* 2012;2:1-13
9. Hughes PJ, Cretton-Scott E, Teague A, et al. Protease Inhibitors for Patients With HIV-1 Infection. *P T.* 2011;36(6):332-45

10. Westby M, van der Ryst E. CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection. *Antivir Chem & Chemother.* 2005;16(6):339-54
11. Moor VJA, Amougou SN, Ombotto S, et al. Dyslipidemia in Patients with a Cardiovascular Risk and Disease at the University Teaching Hospital of Yaounde, Cameroon. *Int J Vasc Med.* 2017;1:1-2
12. Nelson RH. Hyperlipidemia as a Risk Factor for Cardiovascular Disease. *Prim Care.* 2013;40(1):196
13. Helkin A, Stein JJ, Lin S, et al. Dyslipidemia Part I – Review of Lipid Metabolism and vascular Cell Physiology. *Vasc Endovascular Surg.* 2016;50(2):108-9
14. Lin CF, Chang YH, Chien SC, et al. Epidemiology of Dyslipidemia in the Asia Pacific Region. *I J G E.* 2018;12:2-5
15. Feingold KR, Grunfeld C. Introduction to Lipids and Lipoproteins. 2000 [online].<https://www.ncbi.nlm.nih.gov/books/NBK305896/> [Accessed 2019 August 1]
16. National Cholesterol Education Program. Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (adult Treatment Panel III). NH Publication. 2002. Rationale For Intervention. p.5-10
17. Dube MP, Stein JHY, Aberg JA, et. al. Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy : Recommendations of the

- HIV medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. *IDSA*. 2003;37:614-6
18. Feeney ER, dan Mallon PWG. HIV and HAART-Associated Dyslipidemia. *The Open Cardiovasc Med J*. 2011;5:49-63
 19. Aman AM, Soewondo P, Soelistijo, et al. Pedoman Pengelolaan Dislipidemia di Indonesia. PB Perkeni. 2019
 20. Estrada V, dan Prtilla J. Dyslipidemia Related to Antiretroviral Therapy. *AIDS Rev*. 2011;13:49-52
 21. da Cunha J, Maselli L, Stern A, Spada C, dan Bydlowski SP. Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients : Old and new drugs. *World J Virol*. 2015;4(2):56-77
 22. Kemenkes RI. Profil Kesehatan Indonesia 2018 [online]. 2019. p.1-556. <http://www.depkes.go.id/resources/download/pusdatin/profil-kesehatan-indonesia/>. [Accessed 2020 October 16]
 23. Wang HY, Xu JJ, Zou HC, et al. Sexual Risk Behaviors and HIV Infection Among Men Who Have Sex with Men and Women in China : Evidence from a Systematic Review and Meta-Analysis. *Biomed Res Int*. 2015;2015:1-12
 24. Pudjiati SR, Dewi NA, Palupi SS. Correlation between CD4 cell counts with mucocutaneous manifestations : study of HIV patients in Dr.Sardjito General Hospital, Yogyakarta. *J Med Sci*. 2018;50(1):42-9

25. Malvy D, Thiebaut R. Weight loss and body mass index as predictor of HIV disease progression to AIDS in adults. Aquitaine cohort, France 1985-1997. *J Am Coll Nutr.* 2001;20(6):609-15
26. Menteri Kesehatan RI. Pedoman Nasional Pelayanan Kedokteran Tata Laksana HIV. 2019.1-220
27. Singh J, Monica V, Ghalaut PS, et al. Alteration in Lipid Profile in Treatment-Naïve HIV-Infected Patient and Changes Following HAART Initiation in Haryana. *J Endocrinol Metab.* 2014;4(1):25-31
28. Baker JV, Lundgren JD. Cardiovascular implications from untreated human immunodeficiency virus infection. *Eur Heart J.* 2011;32(8):945-51
29. Adewole O, Betiku Y, Eze S, et al. Lipid profile in HIV/AIDS patient in Nigeria. *Afr Health Sci.* 2010;10(2):144-9
30. Sadr WM, Mullin CM, Carr A. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort. *HIV Med.* 2005;6(2):114-21
31. Nsagha DS, Weledji EP, Assob NJ, et al. Highly active antiretroviral therapy and dyslipidemia in people living with HIV/AIDS in Fako Division, South West Region of Cameroon. *BMC Cardiovasc Disord.* 2015;15:95:1-8
32. Leth FV, Phanuphak P, Stroes E, et al. Nevirapin and Efavirenz Elicit Different Changes in Lipid Profile in Antiretroviral-Therapy-Naïve Patients Infected with HIV-1. *Plos Med.* 2004;1(1):1-11